Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults

Prevention of respiratory syncytial virus (RSV) illness in infants is a major public health priority, but there is no approved vaccine. Palivizumab is a monoclonal antibody that provides RSV prophylaxis but requires 5 monthly injections and is approved only for infants who experience the greatest mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffin, M. Pamela, Khan, Anis A., Esser, Mark T., Jensen, Kathryn, Takas, Therese, Kankam, Martin K., Villafana, Tonya, Dubovsky, Filip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2017
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328523/
https://www.ncbi.nlm.nih.gov/pubmed/27956428
http://dx.doi.org/10.1128/AAC.01714-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328523/
https://www.ncbi.nlm.nih.gov/pubmed/27956428
http://dx.doi.org/10.1128/AAC.01714-16

Ejemplares similares